Department of Health
Fourteen Australian start-up and innovative companies will receive funding and commercialisation support to develop:
- devices that address atrial fibrillation, ocular drug delivery, high-risk coronary artery disease, cardiogenic shock, stroke, and preeclampsia
- drugs or treatments for kidney disease, acute ischaemic stroke, diabetic retinopathy, atherosclerotic cardiovascular disease, type 1 and 2 diabetes, diabetic kidney disease and peripheral arterial disease.
Funding is from the Targeted Translation Research Accelerator program under the MRFF's Preventive and Public Health Research initiative. Industry will contribute over $17 million in additional funding to these projects.
Read the media release
/Media Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
